
    
      A multicentre, 1:1 randomised, double blind, double dummy, two arm parallel group phase III
      study comparing a triple modified release tacrolimus FK506E (MR4) / MMF / steroid regimen
      with a triple standard tacrolimus FK506 / MMF / steroid regimen.
    
  